Incidence of type 2 diabetes mellitus in men receiving finasteride and tamsulosin: a cross-validation cohort study using data from China and UK populations
Authors' conclusion
These findings suggest potential benefits of tamsulosin against T2DM and underscore the need for careful monitoring of T2DM risk in finasteride users.
Study context
- Population
- Men aged 40–80 years diagnosed with benign prostatic hyperplasia; EXPLORER database (China) and UK BiobankEXPLORER 34,075
- Exposure
- Finasteride monotherapy, tamsulosin monotherapy and combination therapy vs no treatment
- Outcome
- Incidence of T2DM
Methodological detailscross-validation cohort, overlap weighting, two populations (China and UK)
- Cross-validation cohort
- Overlap weighting
- Two populations (China and UK)
Main finding
As reported in the abstract
T2DM risk
Hazard ratio (95% CI)
Finasteride monotherapyvs Tamsulosin monotherapyEXPLORER
1.36(1.15–1.60)
Finasteride monotherapyvs Tamsulosin monotherapyUKB; not statistically significant
1.32(0.96–1.82)
Finasteride monotherapyvs UntreatedEXPLORER
1.00(0.89–1.13)
Finasteride monotherapyvs UntreatedUKB
1.04(0.77–1.41)
Tamsulosin monotherapyvs UntreatedEXPLORER
0.71(0.64–0.80)
Combination therapyvs UntreatedEXPLORER
0.44(0.40–0.49)
Tamsulosin monotherapyvs UntreatedUKB
0.67(0.56–0.81)
Combination therapyvs UntreatedUKB
0.45(0.34–0.59)
Observational data: associations, not effects.
Original publication
Incidence of type 2 diabetes mellitus in men receiving finasteride and tamsulosin: a cross-validation cohort study using data from China and UK populations. Diabetes Res Clin Pract. Published 6 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →